Please assess the completion status of the following clinical trial:

Trial Title: Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 6 to 23 months~* Evidence of AOM~* Recent (within 48 hours) onset of signs and symptoms.~* Middle ear effusion evidenced by the presence of at least 2 of the following: decreased or absent mobility of the tympanic membrane (TM), yellow of white discoloration of the TM, and/or opacification of the TM~* Acute inflammation evidenced by one of the following: 1+ bulging of the TM with either intense erythema or otalgia or 2+ or 3+ bulging of the TM~Exclusion Criteria:~* Toxic appearance (capillary refill \>3 seconds, systolic blood pressure \<60 mm Hg)~* Inpatient hospitalization~* Clinical or anatomical characteristics that might obscure response to treatment (e.g., tympanostomy tubes in place, cleft palate, Down syndrome)~* Sensorineural hearing loss (unilateral or bilateral)~* Allergy to amoxicillin or amoxicillin clavulanate~* Recent treatment of AOM within the last 14 days

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- amoxicillin-clavulanate potassium (Type: EXPERIMENTAL): amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).